EcoDrugPlus

Plasminogen Activator, Tissue Type

Ensembl ID : ENSBTAG00000001244
Gene Symbol: PLAT
5 Enzyme and pathways 5 Cross references
215 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSBTAG00000027051
Gene Symbol: PTAFR
9 Enzyme and pathways 5 Cross references
236 Possible Orthologues:

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSBTAG00000007173
Gene Symbol: PDGFRA
11 Enzyme and pathways 5 Cross references
216 Possible Orthologues:

Platelet Derived Growth Factor Receptor Beta

Ensembl ID : ENSBTAG00000002804
Gene Symbol: PDGFRB
11 Enzyme and pathways 5 Cross references
259 Possible Orthologues:

Platelet Derived Growth Factor Subunit B

Ensembl ID : ENSBTAG00000021697
Gene Symbol: PDGFB
15 Enzyme and pathways 5 Cross references
275 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSBTAG00000014453
Gene Symbol: PLK1
47 Enzyme and pathways 5 Cross references
199 Possible Orthologues:

Polo Like Kinase 4

Ensembl ID : ENSBTAG00000039552
Gene Symbol: PLK4
16 Enzyme and pathways 5 Cross references
222 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSBTAG00000000837
Gene Symbol: PARP1
26 Enzyme and pathways 4 Cross references
218 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 2

Ensembl ID : ENSBTAG00000009374
Gene Symbol: PARP2
13 Enzyme and pathways 5 Cross references
198 Possible Orthologues:

Poly(Adp-Ribose) Polymerase Family Member 3

Ensembl ID : ENSBTAG00000000671
Gene Symbol: PARP3
5 Cross references
212 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSBTAG00000009282
Gene Symbol: PORCN
5 Cross references
274 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSBTAG00000013300
Gene Symbol: KCNMA1
3 Enzyme and pathways 5 Cross references
313 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).